PDS Biotechnology Corp
PDSBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PDSB Earnings Report
EPS Est: $-0.13 | FQ end 2026-06
How PDSB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab Monotherapy | Phase 3 | Recurrent Head and Neck Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PDS Biotechnology Corp's drug pipeline?→
CatalystAlert tracks 1 drug candidate in PDS Biotechnology Corp's (PDSB) pipeline across Phase 3. Its lead program is Pembrolizumab Monotherapy (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PDS Biotechnology Corp's next FDA catalyst?→
PDS Biotechnology Corp's (PDSB) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PDSB biotech catalysts?→
Add PDSB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PDS Biotechnology Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.